Skip to main content

Table 1 The main characteristics of the studies included in the meta-analysis

From: Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis

Author and year

Patients (n)

TirAEs

(%)

Flare,

n(%)

G1-2,

n(%)

G3-4,

n(%)

New onset irAEs n(%)

G1-2,

n(%)

G3-4,

n(%)

Discont-inuation,

n(%)

ORR

(%)

DCR

(%)

Bhatlapenumarthi-2020 [17]

24

NA

5(20.8%)

NA

NA

NA

NA

NA

NA

NA

NA

Brown-2021 [18]

11

NA

7(63.6%)

5(45.5%)

2(18.2%)

5(45.5%)

NA

NA

NA

45.5%

54.5%

Cortellini-2019 [19]

10

5(50%)

1(10.0%)

1(10.0%)

0

4(40.0%)

4(40.0%)

0

NA

NA

NA

Danlos-2018 [20]

7

NA

1(14.3%)

NA

NA

NA

NA

NA

NA

NA

NA

Efuni-2021 [21]

22

16(72.7%)

12(54.5%)

NA

NA

7(31.8%)

5(22.7%)

2(9.1%)

9(40.9%)

NA

NA

Gutzmer-2017 [22]

9

7(77.8%)

5(55.6%)

3(33.3%)

2(22.2%)

2(22.2%)

2(22.2%)

0

0

44.4%

44.4%

Hoa-2021 [23]

19

12(63.2%)

8(42.1%)

8(42.1%)

0

7(36.8%)

4(21.0%)

3(15.8%)

NA

NA

42.1%

Johnson-2016 [24]

10

7(70.0%)

5(50.0%)

NA

NA

3(30.0%)

0

3(30.0%)

NA

30.0%

NA

Kähler-2017 [25]

14

7(50.0%)

6(42.9%)

NA

NA

4(28.6%)

2(14.3%)

2(14.3%)

1(7.1%)

0

0

Kaur-2019 [26]

5

NA

1(20.0%)

NA

NA

NA

NA

NA

0

NA

NA

Lee-2016 [27]

8

8(100.0%)

6(75.0%)

4(50.0%)

2(25.0%)

NA

NA

4(50.0%)

5(62.5%)

50.0%

87.5%

Leonardi-2018 [28]

25

12(48.0%)

10(40.0%)

7(28.0%)

2(8.0%)

6(24.0%)

4(16.0%)

2(8.0%)

6(24.0%)

NA

NA

Loriot-2020 [29]

7

NA

1(14.3%)

0

1(14.3%)

NA

NA

NA

NA

NA

NA

Lusa-2022 [30]

45

27(60.0%)

13(28.9%)

13(28.9%)

0

20(44.4%)

NA

8(17.8%)

16(35.6%)

13.3%

17.8%

Machado-2023 [31]

58

NA

15(25.9%)

NA

NA

14(24.1%)

NA

NA

NA

NA

NA

Martinez Chanza-2020 [32]

35

23(65.7%)

18(51.4%)

NA

NA

13(37.1%)

NA

NA

NA

NA

NA

Menzies-2016 [33]

27

NA

14(51.9%)

NA

NA

NA

NA

NA

NA

NA

NA

Mitchell-2018 [34]

12

10(83.3%)

10(83.3%)

8(66.7%)

2(16.7%)

3(25.0%)

1(8.3%)

2(16.7%)

3(25.0%)

50.0%

66.7%

Mooradian-2019 [35]

6

NA

6(100%)

NA

NA

2(33.3%)

NA

NA

2(33.3%)

33.3%

66.7%

Panhaleux-2020 [36]

17

NA

4(23.5%)

0

4(23.5%)

10(58.8%)

9(52.9%)

1(5.9%)

NA

41.2%

58.8%

Richter-2017 [37]

16

6(37.5%)

1(6.25%)

1(6.2%)

0

5(31.3%)

1(6.25%)

4(25.0%)

6(37.5%)

NA

NA

Tison-2019 [38]

39

23(58.9%)

19(48.7%)

13(40.6%)

3(9.4%)

NA

NA

NA

6(15.3%)

NA

NA

Van der Kooij-2021 [39]

227

NA

NA

NA

NA

NA

NA

29(12.8%)

NA

NA

NA

  1. Abbreviations: TirAEs, flare, new onset irAEs or both; G1-2, Grade 1 or 2; G3–4, Grade 3 or 4; ORR, objective response rate; DCR, disease control rate; NA, not available